Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
for Acute Myeloid Leukemia (AML)
42 locations incl. Gilbert
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT07007312·Phase 3·Recruiting·Listed Jun 2025